Vimarsana
Biggest News Aggregation in the World

Page 3 - Peter Altman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Peter Altman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Peter Altman Today - Breaking & Trending Today

New Port Richey residents seek cultural center at old Schwettman school - Vimarsana News

New Port Richey residents seek cultural center at old Schwettman school

The former Gulf High School is one of three properties the city has slated for redevelopment.

BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes - Vimarsana News

BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes

SUNNYVALE, Calif., Dec. 18, 2023 -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced...

BioCardia : Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes - Form 8-K -December 18, 2023 at 07:02 am EST - Vimarsana News

BioCardia : Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes - Form 8-K -December 18, 2023 at 07:02 am EST

BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes SUNNYVALE, Calif. - December...

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval - BioCardia (NASDAQ:BCDA) - Vimarsana News

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval - BioCardia (NASDAQ:BCDA)

SUNNYVALE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an

BioCardia Shares Double After FDA Approves CardiAMP Trial - Vimarsana News

BioCardia Shares Double After FDA Approves CardiAMP Trial

By Dean Seal Shares of BioCardia more than doubled after the company said regulators have approved a Phase 3 trial of its CardiAMP treatment for patients...